Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-069226
Filing Date
2025-05-12
Accepted
2025-05-12 16:14:25
Documents
76
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q dnth-20250331.htm   iXBRL 10-Q 2036863
2 EX-31.1 dnth-ex31_1.htm EX-31.1 18945
3 EX-31.2 dnth-ex31_2.htm EX-31.2 19036
4 EX-32.1 dnth-ex32_1.htm EX-32.1 18733
  Complete submission text file 0000950170-25-069226.txt   10233401

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dnth-20250331.xsd EX-101.SCH 1517528
79 EXTRACTED XBRL INSTANCE DOCUMENT dnth-20250331_htm.xml XML 2101382
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38541 | Film No.: 25934998
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)